BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 8010899)

  • 1. Results of external beam radiotherapy in 448 patients with clinically localized adenocarcinoma of the prostate.
    Mameghan H; Fisher R; Mameghan J; Brook S
    Aust N Z J Surg; 1994 Jun; 64(6):389-94. PubMed ID: 8010899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adenocarcinoma of the prostate treated with external-beam radiation therapy: 5-year minimum follow-up.
    Amdur RJ; Parsons JT; Fitzgerald LT; Million RR
    Radiother Oncol; 1990 Jul; 18(3):235-46. PubMed ID: 2120741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymph node-positive prostate cancer: evaluation of the results of the combination of androgen deprivation therapy and radiation therapy.
    Buskirk SJ; Pisansky TM; Atkinson EJ; Schild SE; O'Brien PC; Wolfe JT; Zincke H
    Mayo Clin Proc; 2001 Jul; 76(7):702-6. PubMed ID: 11444402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term results of treatment for prostate carcinoma by staging pelvic lymph node dissection and definitive irradiation using low-dose rate temporary iridium-192 interstitial implant and external beam radiotherapy.
    Puthawala AA; Syed AM; Austin PA; Cherlow JM; Perley JM; Shanberg AM; Sawyer DE; Ingram JE; Baghdassarian R; Wachs BH; Perley JE; Londrc A; Espinoza-Ferrel T
    Cancer; 2001 Oct; 92(8):2084-94. PubMed ID: 11596024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonrandomized evaluation of pelvic lymph node irradiation in localized carcinoma of the prostate.
    Perez CA; Michalski J; Brown KC; Lockett MA
    Int J Radiat Oncol Biol Phys; 1996 Oct; 36(3):573-84. PubMed ID: 8948341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months.
    Akakura K; Suzuki H; Ichikawa T; Fujimoto H; Maeda O; Usami M; Hirano D; Takimoto Y; Kamoto T; Ogawa O; Sumiyoshi Y; Shimazaki J; Kakizoe T;
    Jpn J Clin Oncol; 2006 Dec; 36(12):789-93. PubMed ID: 17082219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complications following external beam radiation therapy for prostate cancer: an analysis of patients treated with and without staging pelvic lymphadenectomy.
    Greskovich FJ; Zagars GK; Sherman NE; Johnson DE
    J Urol; 1991 Sep; 146(3):798-802. PubMed ID: 1908530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of maxillary sinus carcinoma: a comparison of the 1997 and 1977 American Joint Committee on cancer staging systems.
    Le QT; Fu KK; Kaplan M; Terris DJ; Fee WE; Goffinet DR
    Cancer; 1999 Nov; 86(9):1700-11. PubMed ID: 10547542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors in prostate cancer. Analysis of 874 patients treated with radiation therapy.
    Zagars GK; von Eschenbach AC; Ayala AG
    Cancer; 1993 Sep; 72(5):1709-25. PubMed ID: 7688659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer.
    Galalae RM; Kovács G; Schultze J; Loch T; Rzehak P; Wilhelm R; Bertermann H; Buschbeck B; Kohr P; Kimmig B
    Int J Radiat Oncol Biol Phys; 2002 Jan; 52(1):81-90. PubMed ID: 11777625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Moderate hypofractionated external beam radiotherapy alone for intermediate risk prostate cancer: long term outcomes.
    Faria SL; Neto OB; Cury F; Shenouda G; Russel R; Souhami L
    Can J Urol; 2016 Apr; 23(2):8209-14. PubMed ID: 27085825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose-rate brachytherapy as monotherapy for localized prostate cancer: a retrospective analysis with special focus on tolerance and chronic toxicity.
    Yoshioka Y; Nose T; Yoshida K; Oh RJ; Yamada Y; Tanaka E; Yamazaki H; Inoue T; Inoue T
    Int J Radiat Oncol Biol Phys; 2003 May; 56(1):213-20. PubMed ID: 12694841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Higher than standard radiation doses (> or =72 Gy) with or without androgen deprivation in the treatment of localized prostate cancer.
    Kupelian PA; Mohan DS; Lyons J; Klein EA; Reddy CA
    Int J Radiat Oncol Biol Phys; 2000 Feb; 46(3):567-74. PubMed ID: 10701735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: year of treatment an independent predictor of outcome.
    Kupelian PA; Buchsbaum JC; Elshaikh MA; Reddy CA; Klein EA
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):629-34. PubMed ID: 14529766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic importance of Gleason grade in prostatic adenocarcinoma: a long-term follow-up study of 648 patients treated with radiation therapy.
    Zagars GK; Ayala AG; von Eschenbach AC; Pollack A
    Int J Radiat Oncol Biol Phys; 1995 Jan; 31(2):237-45. PubMed ID: 7836075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, NX/N0, M0) adenocarcinoma of the prostate.
    Zagars GK; Pollack A; Smith LG
    Int J Radiat Oncol Biol Phys; 1999 Jul; 44(4):809-19. PubMed ID: 10386637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transperineal percutaneous iridium-192 interstitial template implant of the prostate: results and complications in 321 patients.
    Khan K; Thompson W; Bush S; Stidley C
    Int J Radiat Oncol Biol Phys; 1992; 22(5):935-9. PubMed ID: 1555985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. External beam radiotherapy dose response of prostate cancer.
    Pollack A; Zagars GK
    Int J Radiat Oncol Biol Phys; 1997 Dec; 39(5):1011-8. PubMed ID: 9392538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement in prostate cancer survival over time: a 20-year analysis.
    Kim MM; Hoffman KE; Levy LB; Frank SJ; Pugh TJ; Choi S; Nguyen QN; McGuire SE; Lee AK; Kuban DA
    Cancer J; 2012; 18(1):1-8. PubMed ID: 22290249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Morbidity and mortality of local failure after definitive therapy for prostate cancer.
    Schellhammer PF; Whitmore RB; Kuban DA; el-Mahdi AM; Ladaga LA
    J Urol; 1989 Mar; 141(3):567-71. PubMed ID: 2918594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.